Renal Disease TPE Applications, Therapeutic plasma exchange, Clinical Pathology - Full Vignette with скачать в хорошем качестве

Renal Disease TPE Applications, Therapeutic plasma exchange, Clinical Pathology - Full Vignette with

A 12-year-old girl from a remote mountain town presents during a severe ice storm with sudden pallor, abdominal pain, decreased urine output, and scattered bruising. Her initial labs show anemia, thrombocytopenia, schistocytes on smear, elevated LDH, low haptoglobin, and acute kidney injury. With no diarrhea, negative sick contacts, and delayed diagnostic testing, how would you approach this complex case? Which epidemiologic clues in this clinical context are most important for decision making? VIDEO INFO Category: Renal Disease TPE Applications, Therapeutic plasma exchange, Clinical Pathology Difficulty: Expert - Expert level - For those seeking deep understanding Question Type: Epidemiology Case Type: Resource Limited Explore more ways to learn on this and other topics by going to https://endlessmedical.academy/auth?h... QUESTION A 12-year-old girl from a mountain town in the northern Rockies presents to a critical access hospital during a severe ice storm that has grounded air ambulances and closed mountain passes for an estimated 36-48 hours. She has 1 day of pallor, decreased urine output, abdominal pain, and scattered bruising. She has no diarrhea and no sick contacts. Vaccinations are current. Past history includes retinitis pigmentosa with low-vision aids; no prior kidney disease.... OPTIONS A. Complement-mediated aHUS is ultra-rare, with an annual incidence generally 0.23-1.9 per million and pediatric prevalence around 2-10 per million; in children, approximately 5-25% harbor anti-factor H autoantibodies, a subgroup in which plasma exchange can be a rational temporizing option while de... B. Complement-mediated aHUS occurs in about 1 in 1,000 children annually and most pediatric cases ( greater than 70%) have anti-factor H autoantibodies, making plasma exchange the universal first-line therapy regardless of access to complement inhibitors. C. Complement-mediated aHUS is common in pediatrics ( 1 in 10,000 per year), and fewer than 1% of children have anti-factor H autoantibodies; therefore plasma exchange has no role even when access to eculizumab or ravulizumab is delayed beyond 48 hours. D. Complement-mediated aHUS has a pediatric incidence comparable to Shiga toxin-associated HUS, and anti-factor H antibodies are present in about half of North American children; thus plasma exchange should be preferred over eculizumab whenever ADAMTS13 testing is pending. CORRECT ANSWER A. Complement-mediated aHUS is ultra-rare, with an annual incidence generally 0.23-1.9 per million and pediatric prevalence around 2-10 per million; in children, approximately 5-25% harbor anti-factor H autoantibodies, a subgroup in which plasma exchange can be a rational temporizing option while definitive complement blockade is delayed. EXPLANATION "Complement-mediated aHUS is ultra-rare, with an annual incidence generally 0.23-1.9 per million and pediatric prevalence around 2-10 per million; in children, approximately 5-25% harbor anti-factor H autoantibodies, a subgroup in which plasma exchange can be a rational temporizing option while definitive complement blockade is delayed." This statement is correct and directly informs a resource-limited decision. The epidemiology emphasizes that complement-mediated aHUS is far rarer than STEC-HUS or TTP, but the anti-factor H autoantibody subset is clinically meaningful in pediatrics.... Further reading: Links to sources are provided for optional further reading only. The questions and explanations are independently authored and do not reproduce or adapt any specific third-party text or content. --------------------------------------------------- Our cases and questions come from the https://EndlessMedical.Academy quiz engine - multi-model platform. Each question and explanation is forged by consensus between multiple top AI models (i.e. Open AI GPT, Claude, Grok, etc.), with automated web searches for the latest research and verified references. Calculations (e.g. eGFR, dosages) are checked via code execution to eliminate errors, and all references are reviewed by several AIs to minimize hallucinations. Important note: This material is entirely AI-generated and has not been verified by human experts; despite stringent consensus checks, perfect accuracy cannot be guaranteed. Exercise caution - always corroborate the content with trusted references or qualified professionals, and never apply information from this content to patient care or clinical decisions without independent verification. Clinicians already rely on AI and online tools - myself included - so treat this content as an additional focused aid, not a replacement for proper medical education. Visit https://endlessmedical.academy for more AI-supported resources and cases. This material can not be treated as medical advice. May contain errors. ---------------------------------------------------